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In recent years, as knowledge regarding the etiopathogenetic mechanisms of bone involvement characterizing
many diseases has increased and diagnostic techniques evaluating bone health have progressively improved, the
problem of low bone mass/quality in children and adolescents has attracted more and more attention, and the
body evidence that there are groups of children who may be at risk of osteoporosis has grown. This interest is
linked to an increased understanding that a higher peak bone mass (PBM) may be one of the most important
determinants affecting the age of onset of osteoporosis in adulthood. This review provides an updated picture of
bone pathophysiology and characteristics in children and adolescents with paediatric osteoporosis, taking into
account the major causes of primary osteoporosis (PO) and evaluating the major aspects of bone densitometry in
these patients. Finally, some options for the treatment of PO will be briefly discussed.
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Recently, as knowledge regarding the aetiopathogenetic
mechanisms of many diseases affecting bone health has
increased and the diagnostic techniques for evaluating
bone status have improved, the problem of low bone
mass/quality in children and adolescents has received in-
creased attention, revealing evidence of groups of children
who may be at risk of osteoporosis [1,2]. This interest is
linked to an increased understanding that a higher peak
bone mass (PBM) may be one of the most important de-
terminants affecting the age of onset of osteoporosis in
adulthood [3,4]. Early diagnosis and therapeutic interven-
tion are fundamental for ensuring better bone health in
adulthood. For example, data gathered from 22q11 Dele-
tion Syndrome patients suggests that a reduction in bone
accretion could lead to a pathologically reduced bone
mass in young adults [5]. Alternatively, many studies have
shown that specific types of physical exercise undertaken
during childhood and adolescence may determine bone
health in adulthood, most likely by increasing PBM [6-8].* Correspondence: stefano.stagi@yahoo.it
1Health Sciences Department, University of Florence, Anna Meyer Children’s
University Hospital, Florence, Italy
Full list of author information is available at the end of the article
© 2014 Stagi et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Thus, the achievement of an optimal PBM includes mea-
sures to block reductions in bone apposition or to increase
bone remodelling and bone accrual.
Primary osteoporosis in children occurs due to an in-
trinsic bone abnormality (Primary Osteoporosis, PO) that
is usually genetic in origin, whereas secondary osteo-
porosis arises from an underlying medical condition or its
treatment [9]. In these forms, osteoporosis could be re-
lated to 1) failure to achieve optimal PBM in adolescence,
2) excessive resorption of bone, or 3) failure to adequately
replace the resorbed bone through a bone formation de-
ficit. Although PO is defined by decreased bone strength
that predisposes individuals to fragility fractures, we have
poor long-term follow-up data on bone health in many of
the PO disorders, as well as on bone characteristics,
growth, quality, and density in the pubertal or post-
pubertal periods, on PBM, and on the effects of nutritional
interventions or pharmacological treatments. In order to
understand these issues, it is necessary to know the spe-
cific anatomical and physiological bone characteristics of
children, in addition to the peculiarities in the diagnostic
evaluation of bone density or quality. Because inadequate
acquisition of bone in childhood and adolescence may
lead to an increased lifetime risk of osteoporosis andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Causes of primacy osteoporosis in children and
adolescents
Diseases Genes
Osteogenesis imperfecta COL1A1; COL1A2; IFITM5; SERPINF1;
CRTAP; LEPRE1; PPIB; FKBP10; BMP1;
SP7; SERPINH1; WNT1; TMEM38B
X-linked hypophoshatemic
rickets
PHEX
Homocystinuria CBS
Hypophosphatasia ALPL
Wilson’s disease ATP7B
Menkes’ kinky hair syndrome ATP7A
Osteoporosis-pseudoglioma
syndrome
LRP5
Idiopathic juvenile osteoporosis -
Juvenile Paget’s disease OPG
Early-onset Paget’s disease RANK
Ehler–Danlos syndrome COL5A2; COL5A1; COL1A1; COL3A1;
PLOD1; COL1A2; ADAMTS2; COL3A1;
TNXB
Bruck syndrome FKBP10; PLOD2
Marfan syndrome FBN1
Hypophosphatemic
nephrolithiasis/osteoporosis
SLC34A1; NPHLOP2
Hajdu-Cheney syndrome NOTCH2
Torg-Winchester syndrome MMP2
Shwachman-Diamond syndrome SBDS
Singleton-Merten syndrome -
Cleidocranial dysostosis RUNX2
Stuve-Wiedemann syndrome LIFR
Cole-Carpenter syndrome -
Geroderma osteodysplasticum GORAB
Noonan syndrome PTPN11; SHOC2; KRAS; SOS1; RAF1;
NRAS; BRAF; RIT1
Neonatal hyperparathyroidism CASR
Other forms of
hypophosphatemic rickets
SLC34A3; FGF23; DMP1; ENPP1; CLCN5
Hypocalcemic rickets VDR; CYP2R1; CYP27B1
Note. This table lists only the most frequent diseases associated with primary
osteoporosis according to the recent literature.
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eral status is affected in children with PO.
This review provides an updated picture of the patho-
physiological basis of the main forms of PO in children
and adolescents, taking into account the most common
among the rare syndromes causing PO and evaluating
the main aspects of bone densitometry in these patients.
Finally, treatment options for the various forms of PO
are briefly discussed.
Primary osteoporosis
The primary forms of osteoporosis in childhood are rela-
tively rare, and some of them are familial or genetically
determined (Table 1). The most common primary bone
disorder leading to PO is osteogenesis imperfecta (OI), a
structural genetic defect in the quantity or quality of bone
type 1 collagen production [10]. OI has several subtypes,
ranging from mild forms to a form that causes intrauter-
ine foetal death. Family history, the blue, purple, or grey
sclera commonly observed in this disorder, radiographic
findings, and in some cases, bone biopsy, are used to
establish the diagnosis of the genetic disorder.
Other causes of PO include idiopathic juvenile osteopo-
rosis (IJO), osteoporosis-pseudoglioma syndrome (OPPG),
and X-linked hypophosphatemic rickets (XLH) [11]. En-
zymatic defects such as hypophosphatasia and homo-
cystinuria as well as disorders of copper transport such
as Wilson’s disease and Menkes’ kinky hair syndrome
can also lead to osteoporosis or severe demineralisation
[12,13]. Finally, some genetic syndromes, such as Marfan
and Ehler–Danlos syndrome, or more rare genetic
diseases such as Hajdu-Cheney, Torg-Winchester and
Shwachman-Diamond syndromes, are associated with an
impairment of bone mass or quality.
Osteogenesis imperfecta
OI, or brittle bone disease, a rare heritable connective
tissue disorder, is classified as a form of osteoporosis,
even if the primary defect is genetically altered structure
of type I collagen composing the bone matrix [14]. Typi-
cal features of OI are multiple peripheral and vertebral
compression fractures, blue sclera, excessive joint laxity,
dentinogenesis imperfecta, and hearing loss [14]. The
original classification by Sillence based on phenotypic
features consisted of four types that vary in severity [15].
OI has a birth prevalence of approximately 6 to 7 in
100,000 [16], differing by type, with OI type I and OI
type IV accounting for more than half of all OI cases
[16]. OI type I has a prevalence of 3 to 4 per 100,000
and an incidence of 3.5 per 100,000, whereas the inci-
dence of OI type II is approximately 1 to 2 per 100,000
(the prevalence is not available due to early lethality)
[15,16]. Finally, OI type III has an incidence of 1.6 per
100,000 and a prevalence of 1 to 2 per 100,000 [15,16].OI type IV, which is similar to the other forms, is be-
lieved to be rare.
OI is usually characterised by autosomal dominant in-
heritance (95% of cases), but some cases are related to
autosomal recessive traits or to a spontaneous mutation
[15,17] (Table 2). The OI type I (OMIM #166200) pheno-
type can be produced by a mutation in either COL1A1
(OMIM +120150) or COL1A2 (OMIM *120160), and pos-
sibly in other genes. Type II OI (OMIM #166210) is lethal
in the perinatal period. Type III (OMIM #259420) is a
Table 2 Causes of osteogenesis imperfecta, involved genes, location, inheritance, and gene products
Osteogenesis imperfecta OMIM Inheritance Gene Location Gene product
Type I 166200 AD COL1A1 17q21.33 Collagen, Type I, Alpha-1
Type II 166210 AD COL1A1 17q21.33 Collagen, Type I, Alpha-1
166210 AD COL1A2 7q21.3 Collagen, Type I, Alpha-2
Type III 259420 AD COL1A1 17q21.33 Collagen, Type I, Alpha-1
259420 AD COL1A2 7q21.3 Collagen, Type I, Alpha-2
Type IV 166220 AD COL1A2 7q21.3 Collagen, Type I, Alpha-2
166220 AD COL1A1 17q21.33 Collagen, Type I, Alpha-1
Type V 610967 AD IFITM5 11p15.5 Interferon-induced transmembrane protein-5
Type VI 613982 AR SERPINF1 17p13.3 Serpin peptidase inhibitor
610682 AR CRTAP 3p22.3 Cartilage-associated protein
610915 AR LEPRE1 1P34.2 Leucine- and Proline-Enriched Proteoglycan 1
Type IX 259440 AR PPIP 15q22.31 Peptidyl-prolyl isomerase b
Type X 613848 AR SERPINH1 11q13.5 Serpin peptidase inhibitor, Clade H, Member 1
Type XI 610968 AR FKBP10 17q21.2 FK506-binding protein 10
Type XII 613849 AR SP7 12q13.13 Transcription factor Sp7
Type XIII 614856 AR BMP1 8q21.3 Bone morphogenetic protein 1
Type XIV 615066 AR TMEN38B 9q31.2 Transmembrane Protein 38B
Type XV 615220 AR WNT1 12q13.12 Wingless-type MMTV Integration Site Family, Member 1
Note. This table lists only the most frequent types according to the recent literature.
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BMD [17]. Whereas type I OI patients have a reduced
amount of type I collagen, patients with types II, III and
IV (OMIM #166220) have lower quality type I collagen
[9,18]. Some children with OI do not fall clearly into one
of these four types. In recent years, other additional forms
of OI have been identified (types V-XV) based on a com-
bination of phenotypic and bone histological features
[19,20]. For OI classification, we have used the nomencla-
ture reported in the Online Mendelian Inheritance in Man
(OMIM; http://www.ncbi.nlm.nih.gov/omim) (Table 2).
In OI, musculoskeletal abnormalities include long bone
deformities, with anterior bowing of the humerus, tibia
and fibula, and lateral bowing of the femur, radius and
ulna [9]. Patients have varying degrees of skeletal fragility,
with fractures and bone deformities often occurring after
trivial trauma and manifesting independently of clinical
severity [14]. Other clinical OI manifestations include
short stature, blue sclera, dentinogenesis imperfecta, hea-
ring loss, skin hyperlaxity and joint hypermobility [14].
Scoliosis is a common feature, and the combination of
chest deformities and scoliosis is responsible for res-
piratory disorders, which may also lead to death [14].
Although types I and IV are milder and less easily recog-
nised, they should be considered in the differential diag-
nosis of children with multiple fractures [9,21].
Radiographs commonly reveal cortical bone thinning
and excessive trabecular bone transparency, although
this finding is subjective and difficult to assess withconventional radiography unless there is a significant
reduction in calcified bone mass (approximately 30 to
50%) [22,23]. Bone fragility is also exacerbated by muscle
wasting and immobilisation. Nevertheless, even if none
of the features are specific, their association, together
with a suggestive clinical history (i.e. a propensity for
fractures, family history of pre-senile loss of hearing)
may suffice to confirm OI diagnosis [22].
Management of OI patients is multidisciplinary and
includes specialists in medical OI management, ortho-
paedics, rehabilitation medicine, paediatric dentistry, and
otology/otolaryngology [16]. Mainstays of treatment in-
clude limb braces, orthotics to stabilise lax joints, promo-
tion of appropriate physical activity, muscle strengthening,
pain management, and physical and occupational therapy
to maximise bone stability, improve mobility, prevent
contractures, and prevent head and spinal deformity [16].
Some data suggest that the susceptibility to fractures in
OI arises from low bone mass due to low bone volume
[24-26] or from alterations in the material properties of
bone [27]. Histomorphometric studies conducted on bone
biopsy samples from children with OI types I, III and IV
revealed that bone acquisition during growth is pro-
foundly disturbed due to abnormal bone modelling and
decreased production of secondary trabeculae during
endochondral ossification, as well as decreased thic-
kening of existing trabeculae by bone remodelling [24].
In these patients, early high-resolution transmission
electron microscopy observations of bone fragments
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and unorganised apatite crystals [28]. The bones from
OI patients have a greater mineral content but not a
larger particle width, which in combination with the de-
creased BMD might contribute to compromised bone
strength [29].
In most OI patients, however, BMD is below the nor-
mal range [30], which is the most important risk factor
for further fractures [30]. Commonly, children with OI
are prone to relative bone loss during growth, with im-
pairment of bone accrual and peak bone mass [31,32].
To date, however, only a small number of longitudinal
studies of OI on BMD during growth have been pub-
lished [32-37]. In particular, in 9-year follow-ups, OI pa-
tients appeared to have increased BMD [37].
The use of other techniques for evaluating bone mass
and quality in OI has led to similar results. For example,
peripheral quantitative computed tomography (pQCT)
data suggest that adults with type I OI have an altered
bone geometry and microstructure (lower radius total bone
area, decreased trabecular number, increased trabecular
spacing, and greater trabecular inhomogeneity) and lower
bone mass (decreased areal and volumetric BMD) com-
pared to healthy controls. These results suggest that the in-
creased risk of fractures in patients with type I OI may be
a combined result of altered bone matrix quality, low bone
mass, and altered bone microstructure and geometry [38].
On the other hand, children with OI have low bone quanti-
tative ultrasonography (QUS) values, even if there is no re-
lationship with the number of fractures [39].
Serum calcium is normal in OI subjects, but hypercal-
ciuria has been reported in some patients in the absence
of immobilisation, renal dysfunction or nephrocalcinosis.
Serum 25OH vitamin D [25(OH)D] levels are often low,
indicating a low exposure to sunlight, but serum 25(OH)
D levels appear to be positively associated with aBMD
(areal BMD) z-scores in children and adolescents with
OI types I, III, and IV [40]. Thus, the management of
osteoporosis in OI is important and should focus on
altering bone resorption, the most detrimental part of
bone disease [41].
Although no curative therapy is available for this rare
disease, various pharmacological substances have been
tested as treatments. Over the last two decades, intra-
venous bisphosphonates for treatment of patients with OI
have shown promising results [42]. Poyrazoglu et al.
treated 35 paediatric OI patients with pamidronate. The
treatment was associated with increased BMD scores, de-
creased bone turnover as assessed by bone turnover
markers, and lower fracture rates. It was also found that
earlier age at the onset of therapy was related to a better
response and higher BMD values [42]. Treatment with
cyclic intravenous pamidronate in children younger than
3 years old with moderate to severe OI was well toleratedand associated with increased vertebral BMD and reduced
fracture frequency [43,44]. The impact of at least 2 years
of pamidronate treatment in children with OI revealed an
important improvement in cortical width, trabecular bone
volume and trabecular number [45]. Human growth hor-
mone therapy as an adjunct to neridronate treatment was
also correlated with improved linear growth and increased
BMD [46].
Rauch et al. [47] conducted a double-blind placebo-
controlled study with oral risedronate for mild OI for two
years, providing lower serum bone resorption marker
levels and significantly higher aBMD values compared to
controls. Bishop et al. reported similar findings in a rando-
mised, double-blind, placebo-controlled trial [10]. Finally,
in a randomised 2-year study of oral olpadronate in
children with OI, a 31% reduction in fracture risk was
observed [48].
In another study, Pediatric Outcomes Data Collection
Instrument (PODCI) scores in the sports/physical func-
tioning domain were significantly improved after pami-
dronate therapy [49], and motor milestones were reached
at an earlier age [43]. In OI, physical activity has several
advantages. It provides gravitational stressors required for
bone growth and remodelling, the muscles supporting
joints are strengthened by activity, and as an overall bene-
fit, joint stability is improved [23].
Bruck syndrome
Bruck syndrome (BRKS) is a recessive disorder that was
first described by Bruck in 1897 [50] and is characterised
by congenital contractures and bone fragility. Bruck syn-
drome type 2 (BRKS2; OMIM #609220) is caused by muta-
tions in Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase
2 (PLOD2; OMIM *601865), encoding collagen lysyl hy-
droxylase on chromosome 3q23-q24, whereas Bruck syn-
drome type 1 (BRKS1; OMIM #259450) has been mapped
to chromosome 17p12. This syndrome may be caused by a
homozygous mutation in the FK506-Binding Protein 10
gene (FKBP10; OMIM *607063) on chromosome 17q21
[51]. These data suggest that a set of genes, such as
FKBP10 and PLOD2, act during procollagen maturation to
contribute to molecular stability and post-translational
modification of type I procollagen, without which bone
mass and quality are abnormal [51]. PLOD2 is a member
of the PLOD family of proteins responsible for lysyl hy-
droxylation. PLOD mutations cause Ehlers-Danlos syn-
drome as well as BRKS type 2 [52]. In contrast, FKBP10 is
a member of the immunophilins, a family of proteins with
PPIase activity, which leads to the proper folding of type I
collagen prior to assembly of the triple helices [53].
Clinically, most BRKS patients present with congenital
contractures and pterygia, with white sclera and normal
hearing and vision [54]. The disease progresses relent-
lessly in all patients and leads to severe limb deformities,
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fractures [55]. Bone fractures occur postnatally, whereas
contractures are a primary abnormality and not a com-
plication of fractures [54,55]. Brenner et al. used electron
microscopy to examine a bone specimen from an af-
fected patient and observed osteoblasts with swollen
mitochondria and dilated endoplasmic reticula, as well
as a decrease in the diameter of the collagen fibrils along
with a low mineral content and increased pepsin extrac-
tion of collagen 1 [56].
The data on bone metabolism, density or quality in
BRKS are poor. Plasma calcium and phosphate concentra-
tions appear to be normal in regard to bone formation
markers alkaline phosphatase and procollagen-1 N-pro-
peptide [51]. BMD z-scores are in the normal range, even
if DXA scanning at the spine and femoral sites often pro-
duces artefacts from scoliosis, fractures and acetabular
protrusion [51]. Transiliac bone biopsy results reveal tra-
becular osteopenia and cortical width reduction, without
mineralisation defects [51]. Under polarised light, the bone
has a normal lamellar structure [51]. While orthopaedic
care with fracture management and rehabilitation remain
the cornerstones in the management of all types of OI,
bisphosphonates have been shown to be safe and effective
in the treatment of osteoporosis in BRKS and are now the
gold standard of treatment for this syndrome [57].
Idiopathic juvenile osteoporosis
Idiopathic juvenile osteoporosis (IJO; OMIM 259750) is
a rare disorder recognised by Dent and Friedman in
1965 [58]. It is characterised clinically by an insidious
onset of bone pain, followed by vertebral compression
and repeated fractures of the long bones [59]. The exact
prevalence is unknown, but the estimated incidence is 1
in 100,000 [9]. IJO is usually a self-limiting disease, with
prepubertal onset, typically between 8 and 12 years of
age, and spontaneously resolves after puberty, even if it
may result in severe deformities and functional impair-
ment [59].
Two to three years before the onset of puberty, chil-
dren characteristically experience an insidious onset of
pain in the back and lower extremities in conjunction
with vertebral compression fractures, difficulty in wal-
king, and multiple fractures of the long bones, especially
around the weight-bearing joints [60], without family
history of childhood bone diseases, extra-skeletal ma-
nifestations, or growth impairment [60,61]. Knee and
ankle pain, kyphosis, loss of height and a sunken chest
may also be present. Rarely, in more severe cases, per-
manent disability can develop [61]. The aetiology is un-
clear, although bone histology indicates reduced bone
formation, with a decrease in trabecular bone volume,
thickness and number, but without any alterations in
cortical bone [60,62]. Diagnosis is based on clinicalpresentation, skeletal X-rays and bone density tests
(DXA, pQCT) [60,61].
Using only DXA [63], or DXA and QUS [64], BMD and
bone quality parameters have been reported to be lower
than normal for age. Using DXA and bone biopsy to
examine a cohort of 24 children, it was reported that his-
tomorphometric findings correlated poorly with fracture
history, circulating bone biomarkers and DXA results.
However, it was also observed that vitamin D deficiency
and reduced BMD were associated with high bone turn-
over by biopsy [65]. In a recent study using pQCT and
bone biopsy, JIO patients were characterised by decreased
bone turnover and lower trabecular and cortical BMD
Z-scores, with a relationship between both cortical and
trabecular bone density and parameters of bone histology
[59]. These results support a new method of non-invasive
evaluation of cortical and vertebral bone volume [59].
These data suggest that JIO may be due to the presence of
a normal number of osteoblasts whose function is altered,
leading to a decreased rate of matrix deposition, con-
firming the decreased bone turnover of the majority of pa-
tients, as demonstrated by Rauch et al. [59,62].
The management of JIO is aimed at protecting the spine
and other bones from fracture. Physical therapy and exer-
cise (avoiding weight-bearing activities) and other suppor-
tive measures are mandatory. There is no established
treatment strategy. Treatments with calcium or vitamin D,
fluoride, calcitonin, or anabolic steroids have failed to
modify the course of IJO, with conflicting data showing
improved BMD and fracture rates [65-69].
Bisphosphonates treatment of severe, long-lasting cases
have shown to have unequivocal efficacy [60,61,64], even
if the spontaneous recovery that may occur during skeletal
growth is a confounding factor in examining the effects of
treatments. In a recent study, patients with JIO who were
treated with bisphosphonates had a complete recovery of
painful symptoms, normalisation of bone mineral status at
the phalanges of the hand and lumbar spine, and a reduc-
tion in fracture rate without changes in linear growth,
demonstrating the usefulness of bisphosphonates treat-
ment for this disorder [64].
Juvenile Paget’s disease
Juvenile Paget’s disease (JPD; OMIM #239000) is a rare
autosomal recessive osteopathy characterised biochemi-
cally by markedly increased serum alkaline phosphatase
(ALP) activity emanating from an increased bone turn-
over secondary to enhanced osteoclastic activity [70,71].
Approximately 50 cases have been reported worldwide
[72]. JPD infants and children typically suffer widespread
skeletal involvement manifesting as progressive bone
pain, fractures and deformities, short stature, growth re-
tardation, progressive macrocephaly and facial deformity,
mainly due to maxillary expansion [72,73]. Compression
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nerves, result in deafness and optic atrophy [74].
Most cases of JPD are caused by osteoprotegerin (OPG)
deficiency due to homozygous loss-of-function mutations
within the tumour necrosis factor receptor superfamily
member 11b gene (TNFRSF11B; OMIM #602643) that en-
codes for OPG, located on 8q24.12 [72]. OPG is secreted
into the marrow space by preosteoblasts and osteoblasts,
acting as a decoy receptor for RANKL to its receptor
RANK. Normally, the binding of RANKL to RANK on
osteoclast precursors leads to the activation of osteoclas-
togenesis. By binding to RANKL, OPG reduces its ability
to interact with RANK and thus blocks osteoclast forma-
tion and bone resorption [72,73]. OPG mutation may
therefore lead to uncontrolled osteoclastogenesis.
In JPD patients, X-rays have revealed an undertubula-
tion of long bones with a disorganised trabecular pattern
and thin cortices. Rapid rates of skeletal remodelling have
been demonstrated by histopathology as well as by bio-
chemical markers of bone turnover [74]. Two other condi-
tions considered in differential diagnosis are polyostotic
fibrous dysplasia and hereditary hyperphosphatasia. A
markedly elevated alkaline phosphatase level is unusual in
polyostotic fibrous dysplasia. Although hereditary hyper-
phosphatasia is associated with a high level of alkaline
phosphatase, it manifests much earlier, and radiographs
do not reveal the typical mosaic pattern [72,73]. The mor-
bidity of JPD is very severe, and the majority of children
are wheel-chair bound by age 15 if untreated [74]. Re-
combinant OPG or denosumab, a monoclonal antibody
against the receptor activator of nuclear factor-κ ligand
(RANKL), are promising therapeutic agents [75], but the
data on its use in children are very poor.
Oral bisphosphonate therapy, especially alendronate,
importantly suppresses bone turnover and brings about
remission [76-79]. Early use in paediatric patients prevents
the development of deformities and arrests progression
of the disease and further fractures. Although there is
concern about permanently disturbing bone remodelling
with alendronate, its safe use has been documented in the
paediatric age group in recent studies, at least over the
short term [80]. Calcitonin is a useful adjuvant, especially
for pain relief [81]. In these patients, clinically significant
hypocalcaemia seems to be rare after treatment with
bisphosphonates, particularly after pamidronate, aledro-
nate, or risedronate treatment [82]. Risk factors for severe
bisphosphonate-induced hypocalcaemia include coexis-
ting hypoparathyroidism, vitamin D deficiency, and renal
failure [82].
Early-onset Paget’s disease
Early-onset Paget’s disease (OMIM #603499) of the bone
is a very rare genetic disorder that has been reported in
only a few families [83,84]. This form, which is inheritedin an autosomal dominant pattern, appears commonly
in adolescents or young adults. Its features are similar to
those of the classic form of the disease, although it is
more likely to affect the skull, spine, ribs, and the small
bones of the hands [73,83]. Early-onset Paget disease is
also associated with hearing loss early in life and defec-
tive tooth eruption [85]. People with this disorder have
an altered copy of the tumour necrosis factor receptor super-
family member 11A gene (TNFRSF11A; OMIM #603499),
also known as receptor activator of NF-κe (RANK), located
at 18q21.33 [73,83].
Radiographs of affected bones show lytic and sclerotic
lesions with bony enlargement and deformity. Affected in-
dividuals have very elevated serum alkaline phosphatase
levels (2 to 17 times the normal range) [85]. The data on
treatment options are very sparse. Commonly, surgery has
been employed to correct bone deformities. Bisphospho-
nates have also been used successfully to reduce bone
turnover, although the long-term effects of antiresorptive
therapy on the natural history of the disease remain un-
clear [85].
Hypophosphatasia
Hypophosphatasia (HPP) is a rare inherited disorder char-
acterised by defective bone and tooth mineralisation and
deficiency of the liver/bone/kidney alkaline phosphatase
gene [86,87]. The prevalence of severe forms of the disease
has been estimated at 1/100,000 [88,89]. Based on clinical
course and severity, HP has been divided into 6 major
subtypes. The symptoms are highly variable in their clinical
expression, ranging from stillbirth without mineralised
bone to early loss of teeth without bone symptoms [86-88].
Depending on the age at diagnosis, 6 clinical forms are cur-
rently recognised: perinatal (lethal) (OMIM #241500), peri-
natal benign [86-88], infantile (HOPS; OMIM #241500),
childhood (OMIM #241510), adult (OMIM #146300), and
odontohypophosphatasia (OMIM #146300) [86-93]. In
lethal HPP, the patients show markedly impaired min-
eralisation in utero. This form is characterised by still-
birth or death after birth due to hypoplastic lungs and
respiratory insufficiency, difficult-to-treat seizures, and
hyperkalaemia with extensive hypomineralisation and
bone deformities.
Perinatal benign HPP is characterised by prenatal ske-
letal manifestations that slowly resolve during childhood
or adulthood. Infantile HPP has an onset between birth
and six months without elevated serum alkaline phospha-
tase activity, rickets, premature craniosynostosis, irrita-
bility, seizures or nephrocalcinosis due to hypercalciuria
[89-91]. Childhood hypophosphatasia is characterised by
low bone mineral density for age with unexplained frac-
tures or rickets, causing short stature, delayed walking
and pain of the lower extremities. Premature loss of teeth
often leads to diagnosis [86-91]. Adult HPP presents with
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stress fractures during middle age [92]. Odontohypopho-
sphatasia has been characterised by the premature exfo-
liation of primary teeth or severe dental caries, often not
associated with abnormalities of the skeletal system [93].
HPP is an inborn error of metabolism characterised
biochemically by low serum alkaline phosphatase (ALP)
activity (hypophosphatemia) and caused by a loss-of-func-
tion mutation within the gene encoding tissue-nonspecific
alkaline phosphatase (TNAP) (ALPL; OMIM#171760) on
chromosome 1p36 [86-88]. Consequently, natural sub-
strates of this cell surface enzyme, such as phosphoethano-
lamine (PEA), pyridoxal 5′phosphate (PLP), and inorganic
pyrophosphate (PPi), of this cell surface enzyme accu-
mulate extracellularly [85], blocking hydroxyapatite crystal
propagation and thereby causing rickets during growth or
osteomalacia in adults [86]. There is no curative treatment
for hypophosphatasia, but symptomatic treatments such
as non-steroidal anti-inflammatory drugs or teriparatide
have been shown to be beneficial [94-96]. Enzyme replace-
ment therapy will certainly be the most promising chal-
lenge of the next few years [97].
X-linked hypophosphatemic rickets
X-linked hypophosphatemic (XLH; OMIM #307800)
rickets is a sex-linked dominant disorder of phosphate
homeostasis characterised by defective renal phosphate
handling and vitamin D metabolism, which leads to
growth retardation, rachitic and osteomalacic bone
disease, and hypophosphatemia [98]. Albright first de-
scribed XLH in 1939, and it is the most common form
of inherited rickets, with an incidence of 1 in 20,000
[98]. XLH accounts for more than 80% of familial hypo-
phosphatemic rickets [99].
Inactivating mutations of the Phosphate-regulating gene
with Homologies to Endopeptidase on X chromosome
(PHEX; OMIM *300550) are responsible for the XLH
phenotype [100-102]. PHEX encodes a metalloprotease
that cleaves small peptide hormones and is expressed in
the bones, teeth, and parathyroid glands, but not in the
kidney. Fibroblast growth factor 23 (FGF23) is the major
phosphatonin, and increased levels have been observed in
XLH [99]. It does not seem to cleave FGF23 directly, but
it is involved in the down-regulation of FGF23 by an un-
known mechanism [100]. Such mutations are speculated
to increase the levels of phosphatonins by reduced degra-
dation or increased production [101,103].
Phosphatonins are circulating factors primarily pro-
duced in bone that act on proximal renal tubular cells to
increase phosphate wasting by the down-regulation of
sodium-phosphate co-transporters [101]. In addition, they
reduce the activity of the 1a-hydroxylase enzyme, leading
to inappropriate levels of 1,25 (OH)2 vitamin D3 in the
face of hypophosphatemia [101]. Mutations can bedetected in 50-70% of the affected patients. In addition,
the severity of the disease and specific clinical manifes-
tations are variable even among members of the same
family. In a recent study, patients with clearly deleterious
PHEX mutations that resulted in premature stop codons
had lower tubular reabsorption of phosphate and 1,25
(OH)2D levels than those with plausible causative muta-
tions [103-105].
Untreated XLH is associated with growth retardation
and bone deformities, whereas treatment with oral phos-
phate and vitamin D preparations may improve growth
[104] but is associated with complications, including
nephrocalcinosis, hyperparathyroidism, hypertension, and
cardiovascular abnormalities. Hyperparathyroidism may
be an early event in the development of other compli-
cations, particularly hypertension. Measures to prevent
hyperparathyroidism include the appropriate dosing of
phosphate and vitamin D [104]. In addition to the mine-
ralisation defect induced by hypophosphatemia, an in-
trinsic osteoblast defect also contributes to the bone
disease and does not appear to respond to conventional
treatment [105].
Children and adolescents who are being treated mani-
fest a bone mineral disorder characterised by decreased
BMD in the appendicular skeleton and increased BMD
in the lumbar spine [106]. This outcome has also been
observed in adults during DXA examination of the lum-
bar spine [107]. Bone mineral content was significantly
higher in the XLH cohort in a pQCT study conducted in
children, adolescents and adults with XLH [108]. In
pQCT, XLH patients appear to have elevated trabecular
volumetric bone mineral density (vBMD) at the distal ra-
dius while receiving calcitriol and phosphate supplemen-
tation but low cortical vBMD at the radial diaphysis.
Low cortical vBMD presumably reflects the underlying
mineralisation defect that is not entirely corrected by
current treatment approaches [108]. However, XLH pa-
tients have a muscle function deficit in the lower ex-
tremities, even if bone mass and size are increased at the
distal tibia [109].
Conventional combined treatment of 1,25 dihydroxyvi-
tamin D3 and inorganic phosphate salts has been tho-
roughly demonstrated to improve linear growth and heal
rachitic skeletal abnormalities. However, severe growth
retardation is common in some patients, even with early
medical intervention [98,99]. Moreover, the calcimimetic
drug cinacalcet has been reported to be effective in
XLH [110].
Hypophosphataemic nephrolithiasis/osteoporosis
Hypophosphataemic nephrolithiasis/osteoporosis-1 (NPH
LOP1; OMIM #612286) is caused by a heterozygous muta-
tion in the Solute Carrier Family 34 (Sodium/Phosphate
Cotransporter) Member 1 gene (SLC34A1; *182309) on
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lithiasis/osteoporosis-2 (NPHLOP2; OMIM #612287) is
caused by a heterozygous mutation in the Solute Carrier
Family 9, Member 3, Regulator 1 gene (SLC9A3R1; OMIM
*604990) on chromosome 17q25.1 [112]. Among 20 pa-
tients with urolithiasis or osteoporosis and persistent idio-
pathic hypophosphataemia associated with a decrease in
maximal renal phosphate resorption, two were found to
have mutations in the neomycin phosphotransferase 2
(NPT2) gene [113].Wilson disease
Wilson disease (WD; OMIM #277900) is a rare autosomal
recessive disorder with an estimated prevalence rate of 30
cases per million (i.e. one per 30,000) and an incidence of
one case per 30,000 to 40,000 births [9]. In the United
States, there are approximately 600 cases of WD, and it
has been estimated that 1% of the population are carriers
[113]. A mutation in the ATPase, Cu(2+)-Transporting,
Beta Polypeptide gene (ATP7B; OMIM *606882) located
on chromosome 13q14.3 is responsible for WD [114-116].
Bone and joint involvement are under-recognised com-
ponents of WD, with radiographic evidence of osteopo-
rosis present in up to 88% of persons with the disease
[117-119] that may result in spontaneous fractures. Joint
involvement, particularly of the knees, is also common,
and joint pain has been reported as the presenting symp-
tom of WD [119]. Radiological evidence of vertebral
column abnormalities is evident in 20 to 33% of indivi-
duals with WD [117,120].Menkes’ kinky hair syndrome
Menkes’ kinky hair syndrome (MKD; OMIM #309400) is
a severe multisystem disorder that is caused by defective
bioavailability and transport of copper at the cellular
level. MKD is caused by a mutation in the gene en-
coding Cu(2+)-transporting ATPase, alpha polypeptide
(ATP7A; OMIM *300011) located in Xq21.1 [121,122].
MKD is a rare X-linked recessive disorder with an inci-
dence of approximately 1:298,000 [122]. Classical MKD
is characterised by mental retardation, hypothermia,
seizures, cutis laxa, hypo-pigmentation, abnormal hair
(kinky hair, or pili torti), and decreased serum cerulo-
plasmin levels [121,122].
In these patients, the deficient activity of lysyl oxidase,
a copper-dependent enzyme, causes defective collagen
cross-linking that leads to osteoporosis and pathological
fractures. In a study evaluating the changes in BMD fol-
lowing pamidronate treatment in children with MKD,
increases in lumbar spine BMC and aBMD were re-
ported as 34-55% and 16-36%, respectively, following
1 year of treatment with pamidronate [123]. No further
fractures occurred in two of the three children treated,and no adverse effects of pamidronate treatment were
noted [123].
Osteoporosis-pseudoglioma syndrome
Osteoporosis-pseudoglioma syndrome (OPPG; OMIM
#259770) is a rare autosomal recessive syndrome, with
only approximately 60 cases reported in the literature
[124]. OPPG is characterised by the early onset of severe
symptomatic osteoporosis and the loss of vision in infancy
[125-130]. The vision-loss phenotype is secondary to de-
fective vascularisation. Most patients are congenitally
blind or become blind in early childhood, and all are blind
by the age of 25 years [126,128,131]. Mental development
is usually normal, but approximately 25% of patients have
cognitive impairment [126].
The phenotype is variable, even among siblings [128].
Carriers of the heterozygous mutation also exhibit an
osteoporotic bone phenotype [132-134]. In OPPG pa-
tients, osteoporosis usually manifests in early childhood
with vertebral compression fractures, long bone recurrent
fractures resulting from minimal trauma, and reduced
BMD. More severely affected patients may show muscle
weakness, bowing of the long bones, and severe spinal de-
formities [128,130,135].
In 2001, mutations in the gene encoding low-density lipo-
protein receptor-related protein 5 (LRP5; OMIM *603506)
were detected [126,127]. Numerous loss-of-function mu-
tations have been shown to cause OPPG in individuals
with homozygous or compound heterozygous mutations
[126,136-139]. Additionally, mutations in LRP5 have been
linked to the recessive form of familial exudative vitreoreti-
nopathy (FEVR; OMIM #601813) [140]. In contrast, gain-
of-function mutations in LRP5 may underlie autosomal
dominant disorders with increased bone mass [141]. The
LRP5 expressed in many tissues [142] functions as a
transmembrane coreceptor in the canonical Wnt (wingless)
signalling pathway, which regulates the growth and dif-
ferentiation of osteoblasts [127,136-141,143-147]. More-
over, LRP5 may function indirectly by inhibiting the
expression of Tph1, a rate-limiting enzyme for serotonin in
the duodenum, resulting in higher blood serotonin levels
with inhibited osteoblast proliferation and reduced bone
formation [142]. Of the approximately 60 previously pub-
lished LRP5 mutations associated with OPPG or FEVR,
only a few are splice-site mutations [146,148].
Many heterozygous carriers who underwent bone densi-
tometry were found to have low BMD and diagnoses of
both osteoporosis and osteopenia. This finding is in ac-
cordance with previously published data demonstrating
that heterozygous LRP5 mutations have a predominantly
negative effect on BMD [131,145]. In addition, recent stud-
ies on LRP5 polymorphisms and genome-wide association
studies have revealed that common sequence variants in
LRP5 influence BMD in the general population [149-152].
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Of these, four patients were receiving bisphosphonates
regularly with good responses. Barros et al. [153] reported
similar findings in two brothers with OPPG who were
treated for 4 years and exhibited decreased fracture
events. As a result, the higher BMD was cited as clinically
significant. A marked increase in BMD of the lumbar
spine and femur hip was reported in a study that involved
the administration of teriparatide for 2 years following a
6-year course of intravenous pamidronate infusions [154].
While an increase in CTX followed by an increase in
P1NP is an unusual sequence of events when teriparatide
is used to treat osteoporosis, this finding may be represen-
tative of low bone turnover states [154].
Homocystinuria
Severe hyperhomocysteinaemia (HHcy, total plasma levels
of homocysteine >50 μM) or homocystinuria (OMIM
#236200) can be caused by defects in remethylation
or transsulphuration. Disturbed remethylation due to a
deficiency of 5,10-Methylenetetrahydrofolate Reductase
(MTHFR; OMIM *607093) as well as 5-Methyltetrahydro-
folate-Homocysteine S-Methyltransferase (MTR; OMIM
*156570) [155] result in elevated homocysteine and de-
creased methionine. In the transsulphuration pathway,
CBS deficiency also results in an accumulation of homo-
cysteine, and in contrast to remethylation defects, methio-
nine is increased [156].
Highly variable neurological presentations that range
from schizophrenia and depression to severe mental re-
tardation are common in severe hyperhomocysteinemia,
independently of arterial and venous occlusive disease
and regardless of defects in remethylation or transsul-
phuration [157]. The increased prevalence of osteopo-
rosis in patients with homocystinuria suggests that a
high serum homocysteine concentration may weaken
bone by interfering with collagen cross linking, thereby
increasing the risk of fracture [156]. These findings sug-
gest that the homocysteine concentration, which is easily
modifiable by dietary intervention, is an important risk
factor for hip fractures in older people [158,159].
Homocysteine (Hcy) modulates this process via several
mechanisms, such as by increasing osteoclast activity, de-
creasing osteoblast activity, and by direct Hcy effects on
bone matrix. A detrimental effect on bone is also possible
due to a decrease in bone blood flow and an increase in
matrix metalloproteinases (MMPs) that degrade the extra-
cellular bone matrix. Notably, Hcy has been demonstrated
to bind directly to the extracellular matrix and to reduce
bone strength [158,159]. With regard to whether Hcy af-
fects bone density, earlier studies reported an alteration in
bone biomechanical properties in conditions associated
with deficiencies of vitamin B12, folate, and HHcy. More-
over, existing data leave open to speculation whetherfolate and vitamin therapy also acts via Hcy-independent
pathways [158,159].
Several bone markers may be used to examine the ef-
fects of high levels of plasma Hcy (hyperhomocysteinemia)
on bone, i.e. hydroxyproline and N-terminal collagen 1
telopeptides. In HHcy, mitochondrial abnormalities have
been identified. The mechanism of Hcy-induced bone
remodelling via the mitochondrial pathway is largely un-
known [158,159]. Some studies have demonstrated that
the administration of homocysteine induces osteopenia in
new-born rats [160]. In addition, these data suggest that
hyperhomocysteinemia may disrupt the normal develop-
ment of epiphyseal cartilage in the rat embryo [160]. How-
ever, whereas most homocystinuria patients diagnosed in
adulthood have severe osteoporosis, a good control over
plasma homocysteine appears to prevent or delay some of
these complications [161]. However, more studies are
needed to clarify the mechanistic role of Hcy in bone
diseases.
EhlersnDanlos syndrome
Ehlers-Danlos syndrome (EDS) is an inherited disorder of
connective tissue characterised by hyperextensible skin,
joint laxity, and easy bruising [162,163]. In the more com-
mon EDS types I, II, and III, the underlying genetic defect
is unclear, but a recent study has suggested a linkage with
the COL5A1 gene [162]. The more rare type IV EDS, in
which vascular fragility predominates, results from a defi-
ciency of type III collagen [163,164] (Table 3).
Reduced bone mass does not appear to be one of the
cardinal features of EDS and has not been described in
early reports [165,166]. Nevertheless, some have reported
that nearly 100% of EDS patients may have osteopenia or
osteoporosis [164]. However, osteopenia has been re-
ported to occur in the very rare type VI EDS together with
muscle hypotonia, kyphoscoliosis, and ocular globe rup-
ture [162]. Some recent reports have suggested that bone
density may be reduced in EDS [163,166-168], although
the small sample sizes and possible referral and selection
bias limit the interpretation of these findings. In a case–
control study, EDS patients demonstrated differences in
fracture rates, bone mass, and heel ultrasound parameters
compared with age- and sex-matched controls [166]. Not-
ably, some studies have identified a likelihood of fracture,
low bone mass, and abnormal bone structure among EDS
patients [162,166]. The aetiology is likely to be multi-
factorial with the involvement of an inherited structural
element and may be exacerbated by immobility or re-
duced exercise [162].
Marfan syndrome
Marfan syndrome (MFS; OMIM #154700) is an auto-
somal dominant connective tissue disorder with variable
expressivity and skeletal, cardiovascular, and ocular
Table 3 Causes of Ehlers-Danlos syndrome, genes involved, location, inheritance, and gene product
Ehlers-Danlos syndrome OMIM Inheritance Gene Location Gene product
Type I 130000 AD COL5A2 2q32.2 Collagen, Type -V, Alpha-2
130000 AD COL5A1 9q34.3 Collagen, Type -V, Alpha-1
130000 AD COL1A1 17q21.33 Collagen, Type -I, Alpha-1
Type II 130010 AD COL5A1 9q34.3 Collagen, Type -V, Alpha-1
Type III 130020 AD TNXB 6p21.33 Tenascin XB
Type IV 130050 AD COL3A1 2q32.2 Collagen, Type III, Alpha-1
Type V 305200 - - - -
Type VI 225400 Ad/ar PLOD1 1p36.22 Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase
Type VIIA 130060 AD COL1A1 17q21.33 Collagen, Type I, Alpha-1
Type VIIB 130060 AD COL1A2 7q21.3 Collagen, Type I, Alpha-2
Type VIIC 225410 AR ADANTS2 5q35.2 Procollagen I N-Proteinase
Type VIII 130080 AR - 12p13 -
Note: This table lists only the most frequent types according to the recent literature.
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10,000 subjects [169]. MFS is caused by mutations in the
Fibrillin 1 gene (FBN1; OMIM *134797) [170-172] that
encodes for a glycoprotein that aggregates to form
microfibrils.
FBN1 haploinsufficiency is a major pathogenetic mech-
anism in MFS [173]. Earlier theories proposed that abnor-
mal microfibrils altered the entire fibril structure (with a
predominantly negative effect), thereby resulting in the
disease phenotype. However, certain features in MFS, such
as long bone and rib overgrowth as well as muscle
wasting, cannot be explained by this phenomenon. The
loss of fibrillin 1 protein has a subsequent effect on the
pool of TGF-β, a factor that plays a critical role in bone
health, thus giving rise to various phenotypic manifesta-
tions of the disease [174]. This effect could be modulated
further by different variants of FBN-1, which may explain
the variability in clinical presentation [173,175].
Notably, TGF-β has been demonstrated to positively
regulate osteoblast proliferation and differentiation in vitro
[176], with TGF-β-/- mice exhibiting low bone mass and
poor bone quality [177]. In addition, TGF-β released
during bone resorption induces the migration of bone
mesenchymal stem cells, which differentiate further into
osteoblasts. However, the over-expression of TGF-β from
osteoblasts leads to low bone mass due to the stimulation
of osteoclastogenesis [177]. TGF-β antibody has also been
demonstrated to increase BMD, trabecular thickness, and
bone volume by increasing the number of osteoblasts and
reducing the number of osteoclasts [178]. Moreover,
Fbn1mgR/mgR mice (a model of severe MFS) exhibited
decreased bone volume and density due to TGF-β driven
osteoclastogenesis [179].
Reduced axial and peripheral BMD have been ob-
served in several studies in adults with MFS, suggesting
that these patients are at an increased risk of fractures[180-187]. Conversely, evidence of osteopenia has not
been encountered in some cases [188]. Nonetheless,
there is a paucity of data regarding the bone mineral sta-
tus of MFS patients during childhood. In a study invol-
ving 16 MFS patients, a low BMD at the femoral neck
and a trend towards reduced lumbar spine BMD were
reported [189]. Other data indicated that MFS children
have significantly lower BMC as well as whole-body and
lumbar-spine BMD compared with controls that were
matched for age, sex, height, and ethnicity [189]. In con-
trast, another study reported normal BMD at the lumbar
spine and femoral neck in 21 MFS children [186].
Hajdu-Cheney Syndrome
Hajdu-Cheney syndrome (HJCYS; OMIM #102500) is a
rare autosomal dominant skeletal disorder that was first
reported by Hajdu and Kauntze [190] and later by Cheney
[191]. It is caused by heterozygous activating mutations in
the NOTCH homolog 2 (Drosophila) gene (NOTCH2;
OMIM *600275) on chromosome 1p13-p11. Approxi-
mately 60 cases of HJCYS have been reported [192], and
nearly 24 mutations of NOTCH2 have been identified,
with 12 of these representing missense/nonsense muta-
tions [193].
Notch signalling typically triggers the segmentation of
the axial skeleton during somitogenesis [194] and controls
bone remodelling, particularly suppressing osteoblast mat-
uration and function, and also bone resorption by inducing
osteoprotegerin expression in osteoblasts [194]. HJCYS is
characterised by short stature, coarse and dysmorphic fa-
cies, bowing of the long bones, vertebral anomalies, and
decreased bone density. Facial features include hyperte-
lorism, bushy eyebrows, micrognathia, small mouth with
dental anomalies, low-set ears, and a short neck. These pa-
tients also have wormian bones, open sutures of the skull,
and platybasia. Additional and variable features include
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vus abnormalities (such as an enlarged sella turcica), and
cardiovascular anomalies [195-199].
Progressive focal bone destruction occurs in HJCYS
patients and includes acroosteolysis and severe gene-
ralised osteoporosis [198]. Precocious osteoporosis may
also develop in these patients [200], and marked de-
creases in BMD are evident particularly in the spine as
compared to age-adjusted normal range values [192]. No
definitive studies have indicated the mechanisms res-
ponsible for generalised osteoporosis. Focal osteolysis is
accompanied by neovascularisation, inflammation, and
fibrosis [195,201,202]. Iliac crest biopsies, as reported in a
small number of HJCYS cases, revealed decreased tra-
becular bone, normal or increased bone remodelling, and
normal or decreased bone formation [203-206]. Some
studies have reported that osteoclast activity may be
increased [201,203,204], normal [205,206], or decreased
[202] in HJCYS. However, a reduced rate of bone forma-
tion has also been described [201,203,205].
In these patients, osteoporosis treatment outcomes
have rarely been reported [207-209]. Bisphosphonate
therapy has been attempted alone or in combination
with teriparatide, but there is no clear evidence regar-
ding the actual benefit of these therapies [204,207,210].
Some have demonstrated a good response with an
increase in BMD following teriparatide therapy [208],
whereas others have demonstrated favourable effects of
zoledronic acid therapy [209].
Torg-Winchester syndrome
Torg-Winchester syndrome (TWS; OMIM #259600) is
caused by a mutation in the gene encoding matrix
metalloproteinase-2 (MMP2; OMIM *120360) located in
16q12.2 [210]. The matrix metalloproteinases are a
group of enzymes involved in collagen homeostasis. The
exact mechanism explaining the progression to osteoly-
sis is unknown, but it is believed that abnormal collagen
breakdown may lead to abnormal osteoblast activity with
subsequent osteolysis [211,212].
TWS is an autosomal recessive multicentric osteolysis
with predominant involvement of the hands and feet. In
the past, TWS was reported as 3 separate entities: Torg
syndrome, Winchester syndrome, and NAO syndrome.
The 2006 revision of the Nosology of Constitutional Dis-
orders of Bone classified Torg and Winchester syndromes
as a single entity with NAO syndrome as a variant [213].
Zankl et al. defined the continuous clinical spectrum of
Torg-Winchester syndrome [212]. Torg syndrome is cha-
racterised by the presence of multiple, painless, subcuta-
neous nodules, as well as mild to moderate osteoporosis,
and osteolysis that is usually limited to the hands and feet.
Radiographically, osteolysis is accompanied by a charac-
teristic widening of the metacarpal and metatarsal bones.Winchester syndrome presents with severe osteolysis in
the hands and feet with generalised osteoporosis and bone
thinning, similar to NAO, but subcutaneous nodules are
characteristically absent. Various additional features in-
clude coarse facies, corneal opacities, gum hypertrophy,
and EKG changes. NAO syndrome, which has only been
described in patients from Saudi Arabia, is generally more
severe with multiple prominent and painful subcutaneous
nodules, massive osteolysis in the hands and feet, and
generalised osteoporosis. Coarse facies and body hirsutism
are additional features [214-217].
Mosig et al. generated Mmp2−/− mice and observed
attenuated features of human multicentric osteolysis
with arthritis, including progressive loss of bone mineral
density, articular cartilage destruction, and abnormal
long bone and craniofacial development. These changes
were associated with marked and developmentally re-
stricted decreases in osteoblast and osteoclast numbers
in vivo. Mmp2−/− mice had approximately 50% fewer
osteoblasts and osteoclasts than control littermates at
4 days of life, but these differences were nearly resolved
by 4 weeks of age [218]. Two siblings affected by Torg-
Winchester syndrome were administered intravenous
pamidronate over a period of 3 years with no evidence
of clinical improvement. Although the bone mineral
density of the axial skeleton appeared improved, osteo-
porosis and osteolysis of the appendicular skeleton con-
tinued to worsen [219].
Shwachman-Diamond syndrome
Shwachman-Diamond syndrome (SDS; OMIM #260400)
is a rare autosomal recessive disorder characterised by
exocrine pancreatic insufficiency, bone marrow failure
with varying degrees of hypoplasia and fat infiltration, and
skeletal abnormalities [220]. SDS results from mutations
in the ubiquitously expressed and conserved Shwachman-
Bodian-Diamond syndrome gene (SBDS; OMIM *607444)
[221]. However, SDS defects are relatively organ specific
(i.e. the pancreas, liver, bone marrow, and bone) [222].
SDS patients frequently present with failure to thrive,
susceptibility to infections, and short stature. A persist-
ent or intermittent neutropenia occurs in 88-100% of pa-
tients. Many patients may exhibit skeletal abnormalities,
such as delayed secondary ossification, abnormal devel-
opment of growth plates and metaphyses, progressive
thinning and irregularity of growth cartilage with pos-
sible asymmetric growth, and generalised osteopenia and
osteoporosis [220,223].
In addition to the skeletal dysplasia, SDS is associated
with low bone mass, low bone turnover, and vertebral fra-
gility fractures [224]. Osteoporosis may result from a pri-
mary defect in bone metabolism and may be related to
bone marrow dysfunction and neutropenia [224]. Of note,
Sbds is required for in vitro and in vivo osteoclastogenesis
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clasts of reduced number and size due to impaired migra-
tion and fusion, which are two functions required for
OCG [224]. Phenotypically, Sbds-null mice exhibited low-
turnover osteoporosis, which was consistent with findings
observed in SDS patients [222]. This osteoporosis was
attributed to impaired signalling downstream of the recep-
tor activator of nuclear factor-kB (RANK) and to reduced
expression of the RANK-ligand-dependent fusion receptor
DC-STAMP [222].
In constitutive and inducible SBDS-depleted HeLa cell
clones, a 3- to 6-fold elevation was observed in mRNA
levels of osteoprotegerin (OPG or TNFRSF11B) and
vascular endothelial growth factor-A (VEGF-A) [225].
Osteoprotegerin and VEGF-A are known to have diverse
effects on osteoclast differentiation, angiogenesis, and
monocyte/macrophage migration, all of which are pro-
cesses that may be aberrant in SDS, and we propose that
overexpression of these factors may contribute to the
pathology [224].
Bone biopsies in some SDS patients exhibited significant
low-turnover osteoporosis with reduced trabecular bone
volume, low numbers of osteoclasts and osteoblasts, and a
reduced amount of osteoids [224]. In SDS patients, the
main findings were as follows: (1) markedly reduced BMD
Z-scores at the lumbar spine (median −2.1, range −4.4
to −0.8) and proximal femur (median −1.3, range −2.2
to −0.7) and reduced Z-scores for height-adjusted BMC/
LTM ratio (median −0.9, range −3.6 to +1.1) [223]; (2) ver-
tebral compression fractures in some patients [120]; and
(3) blood biochemistry suggestive of mild vitamin D and
vitamin K deficiency [224].
Discussion
Awareness and recognition of the syndromes and gen-
etic disorders associated with a high risk of osteoporosis
in childhood carry particular relevance in light of recent
research, which has shown that primary osteoporosis
does not truly represent a rare condition [1,226,227].
Moreover, as paediatricians may not recognise the risk
for bone loss in children, treatment for such bone loss
may not be provided. In severe cases of bone loss, as in
osteoporosis, a child may develop fractures or symptoms
[1,227]. In contrast, in cases of less severe but more
chronic forms of bone loss, a child may not attain his or
her genetically determined PBM [4]. Such children may
be at greater risk for adult-onset osteoporosis since they
will enter adulthood with a lower bone mass than would
otherwise be anticipated [4].
While the main factors responsible for the achieve-
ment of peak bone mass in any healthy individual appear
to be genetically determined [228], in children with con-
ditions of reduced mobility who are able to stand, there
is evidence that an increased duration of standing orphysical activity will improve BMD of the spine and
femur [229]. The influence of exercise-induced loading
is further dependent on the stage of skeletal maturity,
with pre- and early puberty representing the develop-
ment intervals during which the skeletal response to
loading is optimised [230]. In addition, Bowden et al.
[231] reported decreased levels of 25-hydroxyvitamin D
among a large group of paediatric patients with osteo-
porosis and osteopenia. Although no direct correlation
with fracture risk was detected, it was surmised that
vitamin D supplementation in children with osteopenia
and osteoporosis is advisable and may indeed reduce
morbidity [5].
The recommended daily consumption of vitamin D may
be insufficient for patients undergoing bone-affecting
treatments and those who suffer from primary bone disor-
ders [5]. In contrast to adult practice, the current evidence
base supporting interventions to potentially prevent osteo-
porosis in children is limited. While calcium and vitamin
D supplementation might appear to comprise an appro-
priate treatment plan for a child with low BMD, there is
no good evidence in paediatric practice to support such
an approach, unless there is evidence of vitamin D defi-
ciency or poor dietary calcium intake [5].
We have summarised the bone density, quality, and
bone metabolism data of some of the more frequent forms
of primary osteoporosis. We have also highlighted the risk
factors for poor bone health, discussed diagnostic tools,
and identified prevention and treatment options. The
main shortcoming highlighted is that for some genetic
diseases or syndromes, the available data related to bone
metabolism, density, and quality are plentiful. For some
diseases, studies have applied new methods such as QUS
or pQCT. The application of these methods may shed
additional light on the characteristic findings with regard
to bone metabolism, structure, density, and quality in
many of the diseases discussed and may also illuminate
other conditions that are associated with primary bone
diseases.
In contrast, we encountered very poor data for many
other genetic diseases or syndromes that were often li-
mited to few case reports. Moreover, studies that were
more than 10 years old lacked attention to data norma-
lisation, e.g. with regard to the height of patients (many
diseases that primarily affect the bone tissue involve the
pubertal stage or skeletal maturation), and thus provided
data of limited utility [232]. The reference data for the
definition of osteoporosis have also changed, which in-
troduced difficulties in making comparisons between dif-
ferent studies [233].
Because the exact pathogenic mechanisms in many
forms of PO have not been clearly established, it is diffi-
cult to proceed with rational drug discovery to specifi-
cally address these mechanisms. In other situations, as
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ther specific therapy or bone-loss prevention strategies
have been addressed adequately by the appropriate in-
vestigations. Frequently, bisphosphonate treatment rep-
resents the first-line therapy for many disorders [1,234].
In many of these conditions, bisphosphonates have also
been studied as a potential preventive measure [1,234].
Although many different bisphosphonates varying in po-
tency and method of administration are currently avail-
able, most of the studies undertaken in children have
utilised intravenous preparations of pamidronate [1]. It
is also evident that most of the studies to date have been
observational, with relatively few randomised controlled
trials [234]. Thus, randomised controlled trials are re-
quired for many other genetic syndromes in which
bisphosphonates are used.
Notably, other new drugs such as recombinant human
parathyroid hormone (rhPTH) may prove useful in the
treatment of primary osteoporosis. However, several
concerns have arisen regarding the safety of such an
agent, particularly in younger patients [235], and results
from additional studies are required before rhPTH can
be accepted as a treatment for OP in children [235].
This may not occur before other specific treatments
such as gene therapy or stem cell transplantation be-
come available for certain genetic bone diseases.Conclusions
Primary osteoporosis in the paediatric population is a rela-
tively rare disorder. While paediatric primary osteoporosis
is characterised by a low incidence of mortality, it carries a
considerable burden of morbidity, particularly due to pain,
interference with regular activities, and long-term seque-
lae. It is the responsibility of the physicians who provide
care to paediatric patients to maintain working knowledge
of the causes of paediatric bone loss so that they may
develop appropriate bone-loss prevention or treatment
strategies.
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